Pharma/Payor Deals An Important Step In The Shift To Value-Based R&D
Three major drug makers inked broad alliances with the research departments of major US payors in 2011. The alliances signal that even as pharma drug makers reorients its R&D engines to be more flexible and externally focused in the hopes of shedding risk and cost, such moves are not enough.
You may also be interested in...
Pharmaceutical companies are beginning to leverage big data to become more integrated into health care delivery, looking to care coordination and other “services adjacent to medicines,” IBM’s John Piccone reports.
A new study by IMS Health shows payers globally are making more drug reimbursement decisions based on real-world evidence – including 25% of more than 100 identified case studies using biopharma industry-generated data.
A wave of research-based collaborations between pharmaceutical companies and payors is enabling a new level of credibility, trust, and joint efforts to enhance patient care.